Novartis cancels Beigene partnership as cancer drug gains EU approval
BioPharma
Source: biopharmadive.com
Page 3 - Mark Lanasa News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Mark Lanasa. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Mark Lanasa Today - Breaking & Trending Today
BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA (tislelizumab)
19.09.2023 - BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that it has entered into an agreement with Novartis to regain worldwide rights to develop, manufacture, and commercialize TEVIMBRA ... Seite 1
Source: wallstreet-online.de
BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)
Regulatory marketing applications for U.S. and EU under review, with plans to expand TEVIMBRA commercial presence worldwide TEVIMBRA is the cornerstone of BeiGene’s solid tumor portfolio,...
Source: marketscreener.com
Novel Gastric Cancer Drug Under FDA Review Improves Survival
Tislelizumab was found to improve overall survival among patients with advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
Source: curetoday.com
Tislelizumab Demonstrates Superior Overall Survival Compared With Chemotherapy
Efficacy and safety data for BeiGene’s therapy shows positive results for individuals with advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Source: pharmacytimes.com